| All Releases |
|---|
 |
Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
Feb 22, 2010
|
15.8 KB
|
| |
ISELIN, N.J., Feb 22, 2010 /PRNewswire via COMTEX News Network/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2009.
Fourth Quarter Ended December 31, 2009
Pharmos has no revenues at this time. The fourth quarter net income is partly due to a renegotia...
|
|
|
Pharmos Corporation Reports 2009 Third Quarter Results
Nov 12, 2009
|
17.9 KB
|
| |
ISELIN, N.J., Nov 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the third quarter and nine-month period ended September 30, 2009.
Third Quarter Ended September 30, 2009The Company recorded a net loss of $1.4 million, or $0.02 per share, for the third quarter ...
|
|
|
Pharmos Corporation Engages Cowen to Assist the Company with Accelerating a Partnership for Dextofisopam
Oct 21, 2009
|
9.2 KB
|
| |
ISELIN, N.J., Oct 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Pink Sheets: PARS); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome. While the results did not achieve ...
|
|
|
Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study
Sep 14, 2009
|
11.2 KB
|
| |
Iselin, NJ, September 14, 2009 - Pharmos Corporation (OTCBB - PARS.PK) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome.
Although the primary efficacy variable (% of weeks responding for adequate overall relief of IBS symptoms) did n...
|
|
|
Pharmos Corporation Reports 2009 Second Quarter Results
Aug 12, 2009
|
71.4 KB
|
| |
Iselin, NJ, August 12, 2009 - Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the second quarter and six-month period ended June 30, 2009.
Second Quarter Ended June 30, 2009
The Company recorded a net loss of $2.3 million, or $0.05 per share, for the second quarter 2009 compared to a net loss ...
|
|
|
Pharmos Corporation Reports 2009 First Quarter Results
May 12, 2009
|
49.2 KB
|
| |
Iselin, NJ, May 12, 2009 - Pharmos Corporation (OTCBB - PARS.PK) today reported results for the first quarter ended March 31, 2009. The Company recorded a net loss of $3.7 million, or $0.14 per share, for the first quarter 2009 compared to a net loss of $3.6 million, or $0.14 per share, in the first quarter 2008. Cash and short-term inves...
|
|
|
Pharmos Completes Private Placement - Raises $1.8 Million
Apr 21, 2009
|
9.7 KB
|
| |
Iselin, NJ, April 21, 2009 - Pharmos Corporation (OTCBB - PARS.PK) announced today that it has completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,8...
|
|
|
Pharmos Issues Business Update on Dextofisopam Trial and Financing
Apr 2, 2009
|
9.5 KB
|
| |
Iselin, NJ, April 2, 2009 - Pharmos Corporation (OTCBB - PARS.PK) issued the following business update on the Dextofisopam Phase 2b trial and the status of financing operations.
Dextofisopam Phase 2b trial
As previously announced on March 4, 2009, Pharmos modified the size of the Dextofisopam Phase 2b trial for I...
|
|
|
Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination Company Also Receives Going Concern Audit Opinion
Mar 6, 2009
|
9.8 KB
|
| |
Iselin, NJ, March 6, 2009 Pharmos Corporation (Nasdaq: PARS) announced today that it has received a Nasdaq Staff Determination that the company is not in compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. Unless the company appeals the determination, its securities will be removed from listing a...
|
|
|
Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
Mar 4, 2009
|
10.7 KB
|
| |
ISELIN, N.J., March 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has completed a reevaluation of the size of the Phase 2b Dextofisopam trial for Irritable Bowel Syndrome IBS -D + A and has concluded that a smaller trial could achieve the objectives of the trial. As the Phase 2...
|
|
|
Pharmos Corporation Reports 2008 Fourth Quarter Results
Feb 27, 2009
|
14.4 KB
|
| |
ISELIN, N.J., Feb 27, 2009 /PRNewswire via COMTEX News Network/ -- ISELIN, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2008.
Fourth Quarter Ended December 31, 2008
The Company recorded a net loss of $1.0 million, or $0...
|
|
|
Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists
Feb 18, 2009
|
9.4 KB
|
| |
ISELIN, N.J., Feb 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has entered into an agreement with an Israel based company, Reperio Pharmaceuticals Ltd. (Reperio) for the sale of the patent rights and technical know how related to the compound known as PRS-639,058 and some foll...
|
|
|
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Nov 19, 2008
|
10.0 KB
|
| |
ISELIN, N.J., Nov 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Study did not achieve statistical significance
Pharmos Corporation (Nasdaq: PARS) today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine.
The multi-center, randomized...
|
|
|
Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
Nov 13, 2008
|
9.1 KB
|
| |
Iselin, NJ, November 13, 2008 - Pharmos Corporation (Nasdaq: PARS) today announced that it received notice from The Nasdaq Stock Market ("Nasdaq") on November 11, 2008 that the Company is not in compliance with Nasdaq Marketplace Rule 4310©(3), which requires the Company to have a minimum of $2,500,000 in...
|
|
|
Pharmos Corporation Reports 2008 Third Quarter Results
Nov 6, 2008
|
54.8 KB
|
| |
Iselin, NJ, November 6, 2008 - Pharmos Corporation (Nasdaq: PARS) today reported results for the third quarter ended September 30, 2008. The Company recorded a net loss of $2.8 million, or $0.11 per share, for the third quarter 2008 compared to a net loss of $3.5 million, or $0.14 per share, in the third quarter 2007. Cash and cash equiva...
|
|
|
Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
Sep 26, 2008
|
8.8 KB
|
| |
Iselin, NJ, September 26, 2008 - Pharmos Corporation (Nasdaq: PARS) today announced that it received a Nasdaq Staff Determination on September 23, 2008 indicating that Pharmos fails to comply with the minimum bid price requirement for continued listing set forth in Marketplace Rule 4310©(4), and that the ...
|
|
|
Pharmos Corporation Announces That it Will Cease Operations in Israel
Aug 29, 2008
|
9.5 KB
|
| |
ISELIN, N.J., Aug 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) today announced that effective October 31, 2008 it will cease operations in Rehovot, Israel, and manage those activities currently based in Rehovot out of the Company's US headquarters in Iselin, New Jersey.
The research programs in I...
|
|
|
Pharmos Corporation Reports 2008 Second Quarter Results
Aug 7, 2008
|
13.2 KB
|
| |
ISELIN, N.J., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the second quarter ended June 30, 2008. The Company recorded a net loss of $2.7 million, or $0.10 per share, for the second quarter 2008 compared to a net loss of $4.6 million, or $0.18 per share, in the second ...
|
|
|
Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
May 14, 2008
|
9.5 KB
|
| |
Iselin, N.J., May 14, 2008 — Pharmos Corporation (Nasdaq: PARS) announced today that its President and Chief Financial Officer, S. Colin Neill, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 5:15 PM Central Europe Daylight Time (GMT +2:00, or 11:15 AM Eastern Day...
|
|
|
Pharmos Corporation Reports 2008 First Quarter Results
May 8, 2008
|
13.0 KB
|
| |
ISELIN, N.J., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the first quarter ended March 31, 2008. The Company recorded a net loss of $3.6 million, or $0.14 per share, for the first quarter 2008 compared to a net loss of $4.8 million, or $0.19 per share, in the first qua...
|
|
|
= Add Release to Briefcase
|
 |
Stock Information
PARS.PK - (OT)
$0.08
- 0.00
|
Mar 10, 2010
3:01 PM ET |
|
